What are the side effects of Zanubrutinib?

The most common adverse reactions of Zanubrutinib are neutropenia (low levels of neutrophils, a type of white blood cell), upper respiratory tract infection (infection of the nose and throat), bleeding, bruising, rash, and musculoskeletal pain; The most common serious side effects are neutropenia, pneumonia (lung infection), high blood pressure, and thrombocytopenia. Zanubrutinib was generally well tolerated, with generally mild to moderate adverse events generally manageable and not associated with frequent treatment interruptions.

Aggregated data from10 clinical trials in B-cell malignancies (including1,550 patients treated with zanubrutinib) showed low rates of treatment discontinuation due to adverse events. The incidence of adverse events of particular interest (such as infection, bleeding, neutropenia, thrombocytopenia, hypertension, anemia, secondary malignancy, and atrial fibrillation/flutter) tended to remain the same or decrease over time. Additionally, zanubrutinib appears to be associated with fewer adverse cardiovascular events compared with ibrutinib. Based on pooled data from the ASPEN and ALPINE studies, the exposure-adjusted incidence of cardiovascular adverse events, including atrial fibrillation (P<0.0001) and symptomatic ventricular arrhythmias (P=0.0028), was significantly lower with zanubrutinib than with ibrutinib.

The original drug of zanubrutinib has been launched in China and has been included in the medical insurance. The price of 80mg*64 capsules per box may be around 6,000 yuan. The original drug of zanubrutinib marketed overseas is relatively expensive. There are currently no generic drugs of zanubrutinib on the market.